| 30.405 -2.425 (-7.39%) | 03-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 40.73 |
1-year : | 44.1 |
| Resists | First : | 34.87 |
Second : | 37.75 |
| Pivot price | 34.66 |
|||
| Supports | First : | 30.2 |
Second : | 25.12 |
| MAs | MA(5) : | 33.59 |
MA(20) : | 34.36 |
| MA(100) : | 35.54 |
MA(250) : | 27.26  |
|
| MACD | MACD : | -0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 23 |
D(3) : | 36.9 |
| RSI | RSI(14): 35.7 |
|||
| 52-week | High : | 42 | Low : | 14.06 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NAMS ] has closed below the lower bollinger band by 26.5%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ NAMS ] is to continue within current trading range. Bollinger Bands are 9.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 32.71 - 32.89 | 32.89 - 33.1 |
| Low: | 29.71 - 29.9 | 29.9 - 30.11 |
| Close: | 30.04 - 30.38 | 30.38 - 30.74 |
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Tue, 03 Mar 2026
NAMS: Obicetrapib's pivotal trials support robust LDL and Lp(a) lowering with broad commercial potential - TradingView
Mon, 02 Mar 2026
NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $14,753,257.75 in Stock - MarketBeat
Mon, 02 Mar 2026
NewAmsterdam Pharma CEO Sells Over $14 Million in Shares - TradingView
Mon, 02 Mar 2026
NewAmsterdam Pharma (NAMS) CEO sells 443,707 shares after option exercise - Stock Titan
Mon, 02 Mar 2026
NewAmsterdam Pharma (NASDAQ: NAMS) files Form 144 to sell 443,707 shares - Stock Titan
Mon, 02 Mar 2026
Obicetrapib data and AD signals in NewAmsterdam (NAMS) deck - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 113 (M) |
| Held by Insiders | 6.923e+007 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 6,210 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.2546e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -206 % |
| Return on Assets (ttm) | 187.5 % |
| Return on Equity (ttm) | -17.3 % |
| Qtrly Rev. Growth | 2.25e+007 % |
| Gross Profit (p.s.) | -1425.72 |
| Sales Per Share | -404.15 |
| EBITDA (p.s.) | 3.21429e+008 |
| Qtrly Earnings Growth | -2.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -148 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.08 |
| Price to Cash Flow | 0.35 |
| Dividend | 0 |
| Forward Dividend | 7.1e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|